NASDAQ:ALEC Alector Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.02 +0.86 (+8.46%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$10.09▼$11.0850-Day Range$7.65▼$11.0252-Week Range$7.50▼$43.32Volume641,758 shsAverage Volume720,456 shsMarket Capitalization$918.26 millionP/E RatioN/ADividend YieldN/APrice Target$29.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Alector Stock Forecast (MarketRank)Analyst RatingModerate Buy2.50 Rating ScoreUpside/Downside170.9% Upside$29.86 Price TargetShort InterestBearish9.55% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1.54 K Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.21 out of 5 starsMedical Sector355th out of 1,428 stocksBiological Products, Except Diagnostic Industry56th out of 217 stocks 3.3 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.86, Alector has a forecasted upside of 170.9% from its current price of $11.02.Amount of Analyst CoverageAlector has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.55% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Alector has recently decreased by 1.87%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlector has received a 68.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alector is -1.03. Previous Next 2.0 News and Social Media Coverage News SentimentAlector has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Alector this week, compared to 2 articles on an average week.Search Interest4 people have searched for ALEC on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Alector to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,542.00 in company stock.Percentage Held by Insiders14.00% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.69% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($1.36) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -26.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -26.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address About Alector (NASDAQ:ALEC)Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More ALEC Stock News HeadlinesJune 24, 2022 | americanbankingnews.comAlector (NASDAQ:ALEC) Shares Up 7.9%June 16, 2022 | investors.comRoche Stock: Alzheimer's Failures Keep Piling Up - Investor's Business DailyJune 11, 2022 | americanbankingnews.comAlector, Inc. (NASDAQ:ALEC) Receives $31.50 Consensus Target Price from BrokeragesJune 10, 2022 | streetinsider.comAlloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines - StreetInsider.comJune 8, 2022 | finance.yahoo.comAlector to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceJune 1, 2022 | nasdaq.comSize Up SBIO as Biotech Catalysts Emerge - NasdaqMay 30, 2022 | seekingalpha.comMorgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking AlphaMay 28, 2022 | finance.yahoo.comAlector Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Yahoo FinanceMay 24, 2022 | benzinga.comGoldman Sachs Maintains Sell on Alector, Lowers Price Target to $6 - Benzinga - BenzingaMay 9, 2022 | finance.yahoo.comAdimab Announces Promotions of New Chief Executive Officer and President - Yahoo FinanceMay 9, 2022 | businesswire.comAdimab Announces Promotions of New Chief Executive Officer and President - Business WireMay 5, 2022 | finance.yahoo.comAlector Reports First Quarter 2022 Financial Results and Provides Business Update - Yahoo FinanceMay 5, 2022 | finance.yahoo.comAlector Reports First Quarter 2022 Financial Results and Provides Business UpdateApril 27, 2022 | nasdaq.comAlector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth - NasdaqApril 27, 2022 | finance.yahoo.comAlector (ALEC) to Report Q1 Results: Wall Street Expects Earnings GrowthApril 26, 2022 | seekingalpha.comHypotheses Underlying Alzheimer's Drug Development - Seeking AlphaApril 13, 2022 | benzinga.comGoldman Sachs Initiates Coverage On Alector with Sell Rating, Announces Price Target of $9 - Benzinga - BenzingaApril 12, 2022 | streetinsider.comNeuron23 Appoints Sam Jackson, MD, MBA, as Chief Medical Officer - StreetInsider.comApril 7, 2022 | benzinga.comMoore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firm - Benzinga - BenzingaMarch 29, 2022 | globenewswire.comAlector Announces Appointment of Gary Romano, MD, Ph.D., as Chief Medical Officer - GlobeNewswireMarch 17, 2022 | finance.yahoo.comNearly seven in 10 Britons are comfortable with less social interaction than pre-pandemic - Yahoo FinanceMarch 16, 2022 | finance.yahoo.comCervical Cancer Epidemiology Forecasts, 2030 - ResearchAndMarkets.com - Yahoo FinanceMarch 15, 2022 | streetinsider.comAlector Inc. (ALEC) Reports AL001 Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial - StreetInsider.comMarch 15, 2022 | globenewswire.comAlector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial - GlobeNewswireMarch 13, 2022 | benzinga.comThe Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conferen - BenzingaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees208Year FoundedN/ACompany Calendar Last Earnings11/04/2021Today7/02/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$29.86 High Stock Price Forecast$57.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+170.9%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.420010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36.33 million Net Margins-12.65% Pretax Margin-12.32% Return on Equity-10.57% Return on Assets-3.81% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual Sales$207.09 million Price / Sales4.43 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book2.98Miscellaneous Outstanding Shares83,327,000Free Float71,661,000Market Cap$918.26 million OptionableNot Optionable Beta1.37 Alector Frequently Asked Questions Should I buy or sell Alector stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Alector stock. View analyst ratings for Alector or view top-rated stocks. What is Alector's stock price forecast for 2022? 6 brokers have issued 1-year price objectives for Alector's stock. Their ALEC stock forecasts range from $6.00 to $57.00. On average, they predict Alector's stock price to reach $29.86 in the next twelve months. This suggests a possible upside of 170.9% from the stock's current price. View analysts' price targets for Alector or view top-rated stocks among Wall Street analysts. How has Alector's stock performed in 2022? Alector's stock was trading at $20.65 at the beginning of 2022. Since then, ALEC stock has decreased by 46.6% and is now trading at $11.02. View the best growth stocks for 2022 here. When is Alector's next earnings date? Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Alector. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Thursday, November, 4th. The company reported $1.49 EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $1.95. The company earned $182.41 million during the quarter, compared to analyst estimates of $407.41 million. Alector had a negative net margin of 12.65% and a negative trailing twelve-month return on equity of 10.57%. View Alector's earnings history. Who are Alector's key executives? Alector's management team includes the following people: Dr. Tillman Ulf Gerngross Ph.D., Co-Founder & Chairman (Age 58, Pay $60k)Dr. Arnon Rosenthal Ph.D., Co-Founder, CEO & Director (Age 66, Pay $972.75k)Dr. Sara Kenkare-Mitra Ph.D., Pres and Head of R&D (Age 54, Pay $552.78k)Mr. Calvin Yu, VP of Fin. (Age 46, Pay $519.69k) (LinkedIn Profile)Dr. Robert S. King, Chief Devel. Officer (Age 59, Pay $658.84k) (LinkedIn Profile)Dr. Marc Grasso M.D., Chief Financial Officer (Age 48)Michelle Corral, VP of Communications & Investor RelationsMs. Danielle Pasqualone J.D., Ph.D., Interim Gen. CounselErica Jefferson, VP of Communications & Public AffairsMs. Clare Hunt M.B.A., Head of People What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Alector's key competitors? Some companies that are related to Alector include Vir Biotechnology (VIR), Abcam (ABCM), Beam Therapeutics (BEAM), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Allogene Therapeutics (ALLO), Immunocore (IMCR), ImmunityBio (IBRX), Revolution Medicines (RVMD) and Recursion Pharmaceuticals (RXRX). View all of ALEC's competitors. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO). When did Alector IPO? (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO. What is Alector's stock symbol? Alector trades on the NASDAQ under the ticker symbol "ALEC." How do I buy shares of Alector? Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alector's stock price today? One share of ALEC stock can currently be purchased for approximately $11.02. How much money does Alector make? Alector (NASDAQ:ALEC) has a market capitalization of $918.26 million and generates $207.09 million in revenue each year. The company earns $-36.33 million in net income (profit) each year or ($0.420010) on an earnings per share basis. How many employees does Alector have? Alector employs 208 workers across the globe. How can I contact Alector? Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for Alector is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com. This page (NASDAQ:ALEC) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here